Ro 3306 Chemical Properties

Boiling point:

569.1±60.0 °C(Predicted)

Density 

1.41

storage temp. 

2-8°C

solubility 

DMSO: soluble5mg/mL, clear

pka

3.99±0.10(Predicted)

form 

powder

color 

white to light brown

Stability:

Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.

Safety Information

WGK Germany 

3

Ro 3306 Usage And Synthesis

Description

RO-3306 (872573-93-8) is a selective inhibitor of CDK1 (IC50?= 35 nM versus CDK2 IC50?= 340nM).1,2?It induces G2/M phase cell cycle arrest and apoptosis. Inhibition of CDK1 with RO-3306 has been shown to have synergistic effects with PARP inhibitors in treating various breast cancers.3,4?It has also been demonstrated to overcome apoptotic resistance in BRAFV600E?human colorectal cancer cells.5

Uses

RO-3306 is an ATP-competitive and selective CDK1 inhibitor used against a diverse panel of human kinases. Used in the treatment of malignant tumors in conjunction with PARP inhibitors.

Uses

RO-3306 has been used:

• To study the significance of CA4-mediated cytotoxicity in mitotic arrest
• In cell cycle synchronization to conduct a study on proteomics
• As a CDK1 inhibitor, to prevent early mitotic entry

Biochem/physiol Actions

RO-3306 is a selective ATP-competitive inhibitor of CDK1. It inhibites CDK1 cyclin B1 activity with Ki of 35 nM, nearly 10-fold selectivity relative to CDK2/cyclin E and over 50-fold relative to CDK4/cyclin D. RO-3306 has been used to cause cell cycle arrest at the G2/M boundary.

IC 50

CDK1: 20 nM (Ki); CDK1/cyclinB1: 35 nM (Ki); CDK1/cyclin A: 110 nM (Ki); CDK2/cyclinE: 340 nM (Ki); PKCδ: 318 nM (Ki); SGK: 497 nM (Ki); ERK: 1980 nM (Ki)

storage

Store at +4°C

References

[1] LYUBOMIR T VASSILEV. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2006: 10660-10665. DOI:10.1073/pnas.0600447103
[2] LILIANA KRASINSKA  Daniel F  Emilie Cot. Selective chemical inhibition as a tool to study Cdk1 and Cdk2 functions in the cell cycle.[J]. Cell Cycle, 2008: 1702-1708. DOI:10.4161/cc.7.12.6101
[3] AISLING PIERCE. Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.[J]. Cancer Biology & Therapy, 2013, 14 6: 537-545. DOI:10.4161/cbt.24349
[4] QING XIA. The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition.[J]. International journal of oncology, 2014, 44 3: 735-744. DOI:10.3892/ijo.2013.2240
[5] PENG ZHANG. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.[J]. Molecular Cancer Research, 2018, 16 3: 378-389. DOI:10.1158/1541-7786.mcr-17-0404

Ro 3306(872573-93-8)Related Product Information

• SU 9516
• NU6102
• OLOMOUCINE
• Etoposide
• Ceritinib
• Axitinib
• BML-275
• 1,9-Pyrazoloanthrone
• PURVALANOL A
• 2(BIS-(HYDROXYETHYL)AMINO)-6-(4-METHOXYBENZYLAMINO)-9-ISOPROPYL-PURINE
• OLOMOUCINE II
• (S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(1-((S)-2,3-dihydroxypropyl)-1H-pyrazol-3-yl)-4-methylpentanamide
• N9-ISOPROPYL-OLOMOUCINE
• (S)-ROSCOVITINE
• ROC-325
• 3,4-dimethoxy-N-[4-(3-nitrophenyl)-1,3-thiazol-2-yl]benzenesulfonamide
• 3,4-difluoro-2-(2-fluoro-4-iodophenylaMino)-N-(2-hydroxyethoxy)-5-((3-oxoMorpholino)Methyl)benzaMide
• RO495